Please login to the form below

Not currently logged in

Marketing authorisation for Boehringer

Boehringer Ingelheim announced on March 27 that marketing authorisation has been granted for its drug Pradaxa

Boehringer Ingelheim announced on March 27 that marketing authorisation has been granted for its drug Pradaxa.

Pradaxa, a oral direct thrombin inhibitor, has been developed and approved for the prevention of postoperative venous thromboembolic events.

Dr Andreas Barner, member of Boehringer's board and responsible for research, development, and medicine, said: "This first licence for our novel oral anticoagulant Pradaxa marks an important advance and milestone in anticoagulation therapy and the prevention of potentially fatal thrombi (blood clots)."

"We remain confident in the potential for Pradaxa to satisfy the unmet medical needs of even more patients and physicians in the future as we continue to invest in our existence RE-VOLUTION clinical trail programme investigating Pradaxa across further therapeutic areas," he added.

Pradaxa is approved for adults who have undergone hip or knee replacement surgery and will be launched in Germany and the UK in the coming weeks.

Dr Bengt Eriksson, principal investigator of RE-NOVATE and RE-MODEL studies, department of orthopaedic surgery at the University Hospital Sahlgrenska, Sweden, said: "The risk of potentially life-threatening thrombosis is a major concern following major orthopaedic surgery."

"Following the approval of Pradaxa, we will have an attractive alternative to other thromboprophylaxis regimens to protect our patients from venous thromboembolism (VTE)," he added.

27th March 2008


Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Beyond the event
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...